Your browser doesn't support javascript.
loading
Target blood pressure and control status in Asia.
Chia, Yook-Chin; Kario, Kazuomi; Turana, Yuda; Nailes, Jennifer; Tay, Jam Chin; Siddique, Saulat; Park, Sungha; Shin, Jinho; Buranakitjaroen, Peera; Chen, Chen-Huan; Divinagracia, Romeo; Hoshide, Satoshi; Minh, Huynh Van; Sison, Jorge; Soenarta, Arieska Ann; Sogunuru, Guru Prasad; Sukonthasarn, Apichard; Teo, Boon Wee; Verma, Narsingh; Zhang, Yuqing; Wang, Tzung-Dau; Wang, Ji-Guang.
Afiliación
  • Chia YC; Department of Medical Sciences, School of Healthcare and Medical Sciences, Sunway University, Bandar Sunway, Malaysia.
  • Kario K; Department of Primary Care Medicine, Faculty of Medicine, University of Malaya, Kuala Lumpur, Malaysia.
  • Turana Y; Division of Cardiovascular Medicine, Department of Medicine, Jichi Medical University School of Medicine, Tochigi, Japan.
  • Nailes J; Department of Neurology, Faculty of Medicine, Atma Jaya Catholic University of Indonesia, Jakarta, Indonesia.
  • Tay JC; University of the East Ramon Magsaysay Memorial Medical Center Inc, Quezon City, Philippines.
  • Siddique S; Department of General Medicine, Tan Tock Seng Hospital, Singapore City, Singapore.
  • Park S; Fatima Memorial Hospital, Lahore, Pakistan.
  • Shin J; Division of Cardiology, Cardiovascular Hospital, Yonsei Health System, Seoul, Korea.
  • Buranakitjaroen P; Faculty of Cardiology Service, Hanyang University Medical Center, Seoul, Korea.
  • Chen CH; Department of Medicine, Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok, Thailand.
  • Divinagracia R; Department of Medicine, Faculty of Medicine, National Yang-Ming University, Taipei, Taiwan.
  • Hoshide S; University of the East Ramon Magsaysay Memorial Medical Center Inc, Quezon City, Philippines.
  • Minh HV; Division of Cardiovascular Medicine, Department of Medicine, Jichi Medical University School of Medicine, Tochigi, Japan.
  • Sison J; Department of Internal Medicine, University of Medicine and Pharmacy, Hue University, Hue, Vietnam.
  • Soenarta AA; Department of Medicine, Medical Center Manila, Manila, Philippines.
  • Sogunuru GP; Department Cardiology and Vascular Medicine, University of Indonesia-National Cardiovascular Center, Harapan Kita, Jakarta, Indonesia.
  • Sukonthasarn A; MIOT International Hospital, Chennai, India.
  • Teo BW; College of Medical Sciences, Kathmandu University, Bharatpur, Nepal.
  • Verma N; Bangkok Hospital Chiang Mai, Chiang Mai, Thailand.
  • Zhang Y; Division of Nephrology, Department of Medicine, Yong Loo Lin School of Medicine, National University of Singapore, Singapore City, Singapore.
  • Wang TD; Department of Physiology, Faculty of Medicine, King George's Medical University, Lucknow, India.
  • Wang JG; Divisions of Hypertension and Heart Failure, Fu Wai Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.
J Clin Hypertens (Greenwich) ; 22(3): 344-350, 2020 03.
Article en En | MEDLINE | ID: mdl-31742891
It is widely accepted that hypertension constitutes a significant cardiovascular risk factor and that treating high blood pressure (BP) effectively reduces cardiovascular risk. An important issue in Asia is not just the high prevalence of hypertension, particularly in some countries, but also the low level of awareness and treatment rates in many regions. The 2017 update of the American College of Cardiology/American Heart Association hypertension guidelines raised the question about which BP threshold should be used to diagnose and treat hypertension. Although there is a theoretical rationale for a stricter BP criterion in Asia given the ethnic-specific features of hypertension in the region, the majority of countries in Asia have retained a diagnostic BP threshold of ≥140/90 mm Hg. Although lowering thresholds might make theoretical sense, this would increase the prevalence of hypertension and also markedly reduce BP control rates. In addition, there are currently no data from robust randomized clinical trials of the benefits of the lower targets in preventing cardiovascular disease and reducing cardiovascular risk, particularly in high-risk patients and especially for Asian populations. There is also no defined home BP treatment target level for an office BP treatment target of 130/80 mm Hg. However, in this regard, in the interim, lifestyle modifications, including reducing body weight and salt intake, should form an important part of hypertension management strategies in Asia, while studies on treating at lower BP threshold level in Asians and getting to lower BP targets will be helpful to inform and optimize the management of hypertension in the region.
Asunto(s)
Palabras clave
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Monitoreo Ambulatorio de la Presión Arterial / Hipertensión Tipo de estudio: Clinical_trials / Diagnostic_studies / Guideline / Risk_factors_studies Límite: Humans País/Región como asunto: America do norte / Asia Idioma: En Revista: J Clin Hypertens (Greenwich) Asunto de la revista: ANGIOLOGIA Año: 2020 Tipo del documento: Article País de afiliación: Malasia Pais de publicación: Estados Unidos
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Monitoreo Ambulatorio de la Presión Arterial / Hipertensión Tipo de estudio: Clinical_trials / Diagnostic_studies / Guideline / Risk_factors_studies Límite: Humans País/Región como asunto: America do norte / Asia Idioma: En Revista: J Clin Hypertens (Greenwich) Asunto de la revista: ANGIOLOGIA Año: 2020 Tipo del documento: Article País de afiliación: Malasia Pais de publicación: Estados Unidos